Quality indicators for colonoscopy: Current insights and caveats.
Hendrikus Jm Pullens, Peter D Siersema
https://pubmed.ncbi.nlm.nih.gov/25512766/Actively Recruiting
Led by Morehouse School of Medicine · Updated on 2025-10-09
300
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are comparing how patients prefer two different bowel preparation methods before a colonoscopy low-volume tablets SuflaveSutab versus the standard large-volume liquid preparation called Golytely. This Phase 4 study involves about 300 adult patients who are scheduled for outpatient colonoscopy. The goal is to understand patient satisfaction, how well patients tolerate each preparation, the completion rates, and how adequately each method cleans the colon for the procedure. Participants will be randomly assigned in a 21 ratio to use either the low-volume tablet options Suflave or Sutab or the standard Golytely liquid preparation. Golytely is a large liquid solution taken in 8-ounce servings every 10 minutes until 4 liters are consumed or until the bowel is clear. Suflave is a split-dose liquid preparation taken in two bottles with flavor packets and additional water. Sutab involves taking tablets with water in two doses one the night before and another six hours before the exam, along with additional water intake. During the study, patients will complete surveys before and after their colonoscopy to share their experiences with the preparation methods. Researchers will evaluate patient satisfaction, tolerance, completion rates, and how well the colon is prepared as seen during the colonoscopy. The study lasts about 12 months, and both preparation methods are FDA-approved and commonly used, so no additional health risks are expected.
CONDITIONS
Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial
J
Julia J Liu, MD, MSc
T
Tasha Rhymes, M.S. Ed.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Morehouse School of Medicine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Sulfave (split-dose liquid prep) | Golytely (large-volume liquid prep) | Sutab (tablet prep) |
|---|---|---|---|
| What is it? | A split-dose liquid bowel cleansing regimen. Sulfave is taken in two separate doses (one bottle plus flavor enhancer each) over two days before colonoscopy. | A large-volume liquid bowel cleansing regimen commonly used before colonoscopy. Participants drink the prescribed Golytely solution as directed prior to their exam. | A tablet-based bowel cleansing regimen. Sutab requires participants to take tablets with water in two stages before their procedure. |
| Role in the trial | Investigational regimen under evaluation for effectiveness and tolerability. | Serves as the active comparator arm against which Sulfave and Sutab are evaluated. | Investigational regimen under evaluation for effectiveness and patient tolerability. |
| Primary use | Aims to achieve effective bowel cleansing before colonoscopy, with the potential for improved patient tolerability via split-dose administration. | Used for bowel cleansing before colonoscopy to achieve adequate visualization of the colon lining. | Designed for bowel cleansing prior to colonoscopy, using tablets instead of liquid to potentially improve patient experience. |
| How is it given or performed? | Given in two split doses (two bottles plus flavor enhancer) across two days before the procedure. | Administered as a large-volume liquid, typically taken over a single session before the colonoscopy. | Taken as 12 tablets with water the evening before and repeated six hours before the colonoscopy, with additional water consumption. |
| Evidence status | Evidence for Sulfave is developing, with recent studies suggesting comparable cleansing effectiveness and tolerability to established regimens. | Golytely's effectiveness as a large-volume bowel cleansing regimen is established by guidelines and numerous clinical studies. | Tablet-based bowel preparations like Sutab have been shown in recent studies to provide effective cleansing, with patient acceptability potentially improved. |
| Important limitations | Split-dose regimens may lead to confusion or incomplete dosing; evidence is still limited about broader outcomes and tolerability across populations. | Golytely's large volume and taste can reduce tolerability for some patients, impacting completion and overall experience. | Tablet-based regimens require swallowing many pills, which may not suit all patients; long-term and broader effectiveness data are still accumulating. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive one of three bowel cleansing drug regimens before their outpatient colonoscopy to prepare their colon for the procedure.
1 day of medication intake before colonoscopy
Duration - Until the end of the study
Participants are monitored after the colonoscopy to assess patient experience, completion rates, and adequacy of the endoscopic procedure.
Visits as needed until study completion
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Hendrikus Jm Pullens, Peter D Siersema
https://pubmed.ncbi.nlm.nih.gov/25512766/Edwin J Lai, Audrey H Calderwood, Gheorghe Doros...
https://pubmed.ncbi.nlm.nih.gov/19136102/Chloe Chien, Libby M Morimoto, Jamie Tom...
https://pubmed.ncbi.nlm.nih.gov/15983985/Ahmir Ahmad, Sarah Marshall, Paul Bassett...
https://pubmed.ncbi.nlm.nih.gov/36944438/Anoop Appannagari, Shikha Mangla, Chuanhong Liao...
https://pubmed.ncbi.nlm.nih.gov/24937514/Nicholas J Ollberding, Abraham M Y Nomura, Lynne R Wilkens...
https://pubmed.ncbi.nlm.nih.gov/21128280/Krishna C Vemulapalli, Rachel E Lahr, Douglas K Rex
https://pubmed.ncbi.nlm.nih.gov/35324481/Andreana N Holowatyj, Julie J Ruterbusch, Laura S Rozek...
https://pubmed.ncbi.nlm.nih.gov/27138583/Patricia V Hernandez, Jennifer L Horsley-Silva, Diana L Snyder...
https://pubmed.ncbi.nlm.nih.gov/32660521/Kristin M Primm, Andrea Joyce Malabay, Taylor Curry...
https://pubmed.ncbi.nlm.nih.gov/37212502/Morehouse School of Medicine
Lead Sponsor